Trials / Completed
CompletedNCT03442764
A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacameten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- MyoKardia, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, exploratory, randomized, double-blind study of the administration of mavacamten in 60 participants with symptomatic nHCM randomized to receive a 16-week course of mavacamten doses titrated to achieve 1 of 2 target drug concentrations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | mavacamten | MYK-461 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2018-03-30
- Primary completion
- 2020-01-07
- Completion
- 2020-01-07
- First posted
- 2018-02-22
- Last updated
- 2022-08-09
- Results posted
- 2022-08-09
Locations
32 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03442764. Inclusion in this directory is not an endorsement.